Bladder cancer is a highly heterogeneous malignancy characterized by frequent genetic alterations that are closely associated with disease progression, recurrence risk, and treatment response. However, existing mutation detection approaches are often limited by high cost, complex workflows, or insufficient capacity for multiplex and low-frequency mutation analysis, which restricts their routine clinical application. The purpose of this study is to establish and clinically validate a multiplex mutation detection system for bladder cancer based on nucleic acid mass spectrometry. Using fresh tumor tissue and matched adjacent normal tissue samples collected from patients with bladder cancer, a targeted mutation panel comprising key functional mutations with demonstrated clinical relevance will be constructed. The matched normal tissues serve as germline references to enable accurate identification of somatic mutations. The analytical performance of the system, including sensitivity, specificity, and concordance with whole-genome sequencing, will be systematically evaluated. In addition, the clinical utility of the mutation panel in risk stratification and treatment decision support will be explored by comparing its predictive value with established clinical models and guideline-recommended tools. The ultimate goal is to develop a cost-effective, reproducible, and clinically applicable molecular testing strategy that can support precision diagnosis and individualized management of patients with bladder cancer.
Histologically confirmed diagnosis of urothelial carcinoma of the bladder (any stage, including non-muscle invasive and muscle invasive).
Availability of sufficient tumor tissue specimen (fresh frozen) for DNA extraction and mutation analysis.
Age ≥ 18 years at time of diagnosis.
History of other malignant tumors within the past 5 years, except adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix.
Inadequate quality or quantity of tumor tissue DNA for mutation panel analysis (e.g., severe DNA degradation, insufficient DNA yield).
Pregnancy or breastfeeding.
Serious uncontrolled intercurrent illness that would interfere with study follow-up or compliance, including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
This study will include adult patients aged 18 years or older with a histologically confirmed diagnosis of urothelial carcinoma of the bladder, including both non-muscle invasive bladder cancer and muscle invasive bladder cancer. Eligible participants must have sufficient fresh frozen tumor tissue samples available for DNA extraction and mutation analysis. Exclusion criteria include inadequate tumor tissue DNA quality for mutation analysis, pregnancy or breastfeeding, and serious uncontrolled intercurrent illnesses that may interfere with study participation. The study population will be representative of bladder cancer patients receiving standard clinical management, focusing on genetic mutation profiling for improved risk stratification and treatment prediction.
Cohort
Prospective
Multiplex Mutation Detection System for Bladder Cancer (Nucleic Acid Mass Spectrometry)
GeneticThis study uses a multiplex mutation detection system for bladder cancer based on nucleic acid mass spectrometry. The system is designed to identify genetic alterations in bladder cancer-related genes, including Fibroblast Growth Factor Receptor 3 (FGFR3), Tumor Protein P53 (TP53), and other relevant genes. The platform offers high-throughput, multiplex mutation detection with high analytical sensitivity and cost efficiency, suitable for potential clinical use. Tumor tissue samples will be prospectively collected from patients with bladder cancer who elect to undergo surgery. The study is observational, with no active intervention, therapeutic modification, or influence on clinical treatment decisions. Mutation status from tissue analysis will be evaluated for correlations with clinical outcomes, including recurrence, progression, and treatment response.
Survival Differences Between Mutated and Non-mutated Groups in Bladder Cancer Patients
This outcome measure aims to compare the survival rates between bladder cancer patients with mutations in key bladder cancer-related genes (as determined by the multiplex mutation detection panel) and those without mutations. The mutation status (any gene mutation versus no mutation) will be correlated with clinical outcomes, including recurrence-free survival (RFS), progression-free survival (PFS), and overall survival (OS), using Kaplan-Meier survival analysis. These survival metrics will be assessed to determine whether mutation status influences prognosis and to identify any significant survival differences between mutated and non-mutated groups.
Development of Predictive Models for Post-surgical Recurrence, Progression, and Response to Intravesical Therapy
This secondary outcome measure focuses on identifying risk factors for post-surgical recurrence, progression, and response to intravesical therapy using a multivariable Cox proportional hazards regression analysis. Factors such as tumor stage, number of tumors, age, and mutation status will be included in the prediction model to assess the likelihood of recurrence and progression. The model will integrate the mutation panel to refine risk stratification and support clinical decision-making.
Validation of Mutation Panel's Predictive Value in Risk Stratification Using Existing Clinical Models
This measure will assess the performance of the mutation panel in predicting patient outcomes compared to established clinical models, such as the European Association of Urology (EAU), the European Organisation for Research and Treatment of Cancer (EORTC), and the Spanish Urological Club for Oncological Treatment (CUETO). The mutation panel's predictive value will be compared with these models for risk stratification in different risk groups (extremely high, high, medium, low risk). The goal is to validate the effectiveness of the mutation panel as an additional tool for patient stratification and prediction of recurrence.
Click on the lead sponsor to view all of their trials.
Zhilong Dong
Lead sponsor
Lanzhou University Second Hospital
Sponsor institution
